Stay updated on REOLYSIN in KRAS Mutant CRC Clinical Trial
Sign up to get notified when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.

Latest updates to the REOLYSIN in KRAS Mutant CRC Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has been updated to include specific drug names and details related to KRAS mutant metastatic colorectal cancer treatment, while significant portions of the previous content describing the study's methodology and eligibility criteria have been removed.SummaryDifference39%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check87 days agoChange DetectedThe web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check94 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to REOLYSIN in KRAS Mutant CRC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the REOLYSIN in KRAS Mutant CRC Clinical Trial page.